BioCardia Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
IPO Year:
Exchange: NASDAQ
Website: biocardia.com
Recent Analyst Ratings for BioCardia Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2021 | $9.00 | Buy | HC Wainwright & Co. |
BioCardia Inc. Press Releases
Fastest customizable press release news feed in the world
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2024 on Wednesday, March 26, 2025, and will host a corporate update conference call on Monday, March 31, 2025 (time and dial-information to be announced). The conference call will follow the presentation, "A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial," at the American College of Cardiology 2025 Scientific Sessions
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System
SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled "Radial and Transendocardial Delivery Catheter" with a patent term that will expire on or after September 30, 2034. "This new patent in Japan adds to our growing patent position with respect to minimally invasive catheter-based delivery systems for cell and gene-based therapies to the heart," said Dr. Peter Altman, BioCardia CEO. "Our clinical cell therapy candidates for the treatment of ischem
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions
SUNNYVALE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the completion of source data verification and freezing of primary outcomes data in the double-blind randomized placebo-controlled Phase 3 CardiAMP HF study of its autologous minimally invasive cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF). Data from the 115 randomized patients in the study has been transferred to the Statistical Data Analysis Center core laboratory for analysis. Results are scheduled to be presented at the Late
BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)
Focus on Patients with Elevated Markers of Heart Stress and Inflammation Procedural enhancement using FDA Approved Morph DNA steerable guide for therapeutic delivery SUNNYVALE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today completion of enrollment and dosing in the low dose cohort in its CardiALLO™ Allogeneic Mesenchymal Cell Therapy Phase I/II trial. The trial is designed to treat patients with ischemic heart failure of reduced ejection fraction (HFrEF) and is believed to be the world's first prospective trial of allogeneic mese
BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions
SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA) today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have been accepted for presentation in a late-breaking symposium at the American College of Cardiology 2025 Scientific Sessions, taking place in Chicago, March 29-31, 2025. Title: A Double Blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF TrialPresenter: Amish N. Raval, M.D., Professor of Medicine and Biomedical Engineering, Chair of Cardiovascular Regenerative Medicine Focus Group, and Medical Director of UW Health S
BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family
SUNNYVALE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the commercial availability of its Morph DNA steerable introducer product family, currently utilized in the Company's ongoing cell-therapy clinical trials. "Our team is exploring an initial sales pipeline organically, without expending the operating costs associated with engaging a direct sales force or third-party medical device commercial partners." said BioCardia CEO, Peter Altman, PhD. "We look forward to demonstrating the value of the Morph DNA product family to physici
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure
SUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the successful completion of a consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on the next steps for the submission for registration of its lead therapeutic asset, BCDA-01, for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF). "This most recent meeting with PMDA had several important outcomes," said Peter Altman, Ph.D., BioCardia's President and Chief Executive Officer." First, PMDA has invited our next consultation a
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
SUNNYVALE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2024 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduce
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
SUNNYVALE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration.
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
SUNNYVALE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the completion of its last protocol specified follow-up visit in CardiAMP HF, a prospective, randomized, double-blinded, placebo procedure controlled, multi-center pivotal clinical trial for the treatment of heart failure of reduced ejection fraction (HFrEF). The CardiAMP HF Trial is assessing the safety and effectiveness of the CardiAMP® Cell Therapy System for HFrEF, with the potential to reduce all cause death, future hospitalizations, enhance functional capacity, as well
BioCardia Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
HC Wainwright & Co. initiated coverage on BioCardia with a new price target
HC Wainwright & Co. initiated coverage of BioCardia with a rating of Buy and set a new price target of $9.00
BioCardia downgraded by Dawson James
Dawson James downgraded BioCardia from Buy to Neutral
BioCardia Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Director Stertzer Simon H bought $2,450 worth of shares (1,000 units at $2.45), increasing direct ownership by 2% to 57,138 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
Director Stertzer Simon H bought $88,065 worth of shares (38,289 units at $2.30), increasing direct ownership by 215% to 56,138 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $1,055 worth of shares (500 units at $2.11), increasing direct ownership by 0.46% to 108,420 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $1,488 worth of shares (600 units at $2.48), increasing direct ownership by 0.56% to 107,920 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $1,769 worth of shares (739 units at $2.39), increasing direct ownership by 0.69% to 107,320 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $2,060 worth of shares (1,000 units at $2.06), increasing direct ownership by 0.95% to 106,581 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $555 worth of shares (250 units at $2.22), increasing direct ownership by 0.24% to 105,581 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $2,524 worth of shares (1,350 units at $1.87), increasing direct ownership by 1% to 105,331 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $1,513 worth of shares (500 units at $3.03), increasing direct ownership by 1% to 39,745 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $1,645 worth of shares (500 units at $3.29), increasing direct ownership by 1% to 39,245 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
BioCardia Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Director Stertzer Simon H bought $2,450 worth of shares (1,000 units at $2.45), increasing direct ownership by 2% to 57,138 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
Director Stertzer Simon H bought $88,065 worth of shares (38,289 units at $2.30), increasing direct ownership by 215% to 56,138 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $1,055 worth of shares (500 units at $2.11), increasing direct ownership by 0.46% to 108,420 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $1,488 worth of shares (600 units at $2.48), increasing direct ownership by 0.56% to 107,920 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $1,769 worth of shares (739 units at $2.39), increasing direct ownership by 0.69% to 107,320 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $2,060 worth of shares (1,000 units at $2.06), increasing direct ownership by 0.95% to 106,581 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
Senior Vice President, Devices Gillis Edward M sold $6,514 worth of shares (3,257 units at $2.00), decreasing direct ownership by 27% to 8,968 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $555 worth of shares (250 units at $2.22), increasing direct ownership by 0.24% to 105,581 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
President and CEO Altman Peter bought $2,524 worth of shares (1,350 units at $1.87), increasing direct ownership by 1% to 105,331 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
Senior Vice President, Devices Gillis Edward M gave a grant of 15,808 shares and covered exercise/tax liability with 6,840 shares, decreasing direct ownership by 65% to 12,225 units (SEC Form 4)
4 - BioCardia, Inc. (0000925741) (Issuer)
BioCardia Inc. SEC Filings
BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - BioCardia, Inc. (0000925741) (Filer)
BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - BioCardia, Inc. (0000925741) (Filer)
BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - BioCardia, Inc. (0000925741) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by BioCardia Inc.
SCHEDULE 13G/A - BioCardia, Inc. (0000925741) (Subject)
BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - BioCardia, Inc. (0000925741) (Filer)
BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - BioCardia, Inc. (0000925741) (Filer)
BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - BioCardia, Inc. (0000925741) (Filer)
SEC Form 424B5 filed by BioCardia Inc.
424B5 - BioCardia, Inc. (0000925741) (Filer)
BioCardia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - BioCardia, Inc. (0000925741) (Filer)
SEC Form 10-Q filed by BioCardia Inc.
10-Q - BioCardia, Inc. (0000925741) (Filer)
BioCardia Inc. Financials
Live finance-specific insights
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2024 on Wednesday, March 26, 2025, and will host a corporate update conference call on Monday, March 31, 2025 (time and dial-information to be announced). The conference call will follow the presentation, "A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial," at the American College of Cardiology 2025 Scientific Sessions
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
SUNNYVALE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration.
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights BCDA-01: CardiAMP® autologous cell therapy in ischemic heart failure of re
BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2024 by conference call on Tuesday, August 13, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10191562/fd3d36338a. Please note that registered participants will receive their dial-in number upon registration. For those who have not
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2024 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. First Quarter 2024 Highlights CardiAMP™ autologous cell therapy for patients with ischemic heart failure obser
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the the three months ended March 31, 2024 and provide a corporate update by conference call on Tuesday, May 14, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10189148/fc87734564. Please note that registered participants will receive their dial-in number upon registration. For those who have no
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial. The Company will report results from this trial and host a call with study clinical cardiology leadership to review the opportunity, early positive results, and randomized study on Tuesday, April 30, 2024, at 3:00 PM ET. Participants can register for the conference by navigating to https://dpreg
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2023 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights with call details below. "Heart failure of reduced ejection fraction or HFrEF remains an unmet clinical need with none of the recently approved therapies reducing mortality," said BioCardia CEO Peter Altman, Ph.D. "The interim da
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2023 and provide a corporate update by conference call on Wednesday, March 27, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10187416/fbec8cfa30. Please note that registered participants will receive their dial-in number upon registration. For those who have n
BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2023 and filed its quarterly report on Form 10-Q for the three and nine months ended June 30, 2023 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. "We have increased confidence in the potential of our autologous CardiAMP Cell Therapy program in isch
BioCardia Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G filed by BioCardia Inc.
SC 13G - BioCardia, Inc. (0000925741) (Subject)
SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)
SC 13D/A - BioCardia, Inc. (0000925741) (Subject)
SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)
SC 13D/A - BioCardia, Inc. (0000925741) (Subject)
SEC Form SC 13G/A filed by BioCardia Inc. (Amendment)
SC 13G/A - BioCardia, Inc. (0000925741) (Subject)
SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)
SC 13D/A - BioCardia, Inc. (0000925741) (Subject)
SEC Form SC 13G/A filed by BioCardia Inc. (Amendment)
SC 13G/A - BioCardia, Inc. (0000925741) (Subject)
SEC Form SC 13G filed by BioCardia Inc.
SC 13G - BioCardia, Inc. (0000925741) (Subject)
SEC Form SC 13G/A filed by BioCardia Inc. (Amendment)
SC 13G/A - BioCardia, Inc. (0000925741) (Subject)
SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)
SC 13D/A - BioCardia, Inc. (0000925741) (Subject)
SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)
SC 13D/A - BioCardia, Inc. (0000925741) (Subject)